Mechanisms of first-line treatment resistance in diffuse large B-cell lymphoma
Zhumei Zhan, Peipei Li, Yanlu Liu, Changqing Zhen, Ying Zhang, Ou Bai · 2026
Read Mechanisms of first-line treatment resistance in diffuse large B-cell lymphoma by Zhumei Zhan, Peipei Li, Yanlu Liu, Changqing Zhen, Ying Zhang, Ou Bai (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13194105.txt.
Description
Zhumei Zhan and five co-authors review, in a 2026 paper, why first-line treatment fails for a common adult lymphoma. Diffuse large B-cell lymphoma is the most frequent subtype of malignant lymphoma in adults. Sixty to seventy percent of patients reach remission on standard immunochemotherapy. The rest see the disease resist care or come back, and that group drives most deaths.
The review walks through the molecular mechanisms the cancer uses to resist each drug in the standard regimens. One point stands out: the components of the regimens do not boost each other much, but cross-resistance between the two main regimens is minimal. That leaves room to switch when one fails. The authors close with strategies for the rational management of resistant cases, drawn from the mechanisms mapped. The piece aims to guide both clinical decisions and new drug work.
Catalog record
| CREATOR | Zhumei Zhan, Peipei Li, Yanlu Liu, Changqing Zhen, Ying Zhang, Ou Bai |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |